The predictive value of combined detection of serum tumor abnormal protein, cytokeratin 19 fragment antigen and endothelial cell specific molecule 1 in postoperative recurrence and metastasis of colorectal cancer patients
10.3760/cma.j.cn115455-20230911-00234
- VernacularTitle:血清肿瘤异常蛋白、细胞角蛋白19片段抗原及内皮细胞特异性分子１联合检测对结直肠癌患者术后复发转移的预测价值
- Author:
Yaoying ZHENG
1
;
Junchao ZHOU
1
Author Information
1. 浙江金华广福肿瘤医院重症医学科，金华 321000
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Tumor abnormal protein;
Cytokeratin 19 fragment antigen;
Endothelial cell specific molecule 1;
Recidivism
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(2):146-150
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the predictive value of combined detection of serum tumor abnormal protein (TAP), cytokeratin 19 fragment antigen (CYFRA21-1), and endothelial cell specific molecule 1 (ESM1) for postoperative recurrence and metastasis of colorectal cancer patients.Methods:Seventy-five patients with colorectal cancer(colorectal cancer group) admitted to Jinhua Guangfu Cancer Hospital from June 2021 to May 2023 and 60 healthy subjects (control group) during the same period were retrospectively selected as the study objects. The levels of serum TAP, CYFRA21-1 and ESM1 were compared between the two groups. The levels of serum TAP, CYFRA21-1 and ESM1 in colorectal cancer patients with different clinicopathological features were compared. All patients with colorectal cancer were followed up for 1 year, and 5 cases were lost to follow-up, including 40 cases in the non-recurrence and metastasis group and 35 cases in the recurrence and metastasis group. The levels of serum TAP, CYFRA21-1, and ESM1 were compared between the two groups. The receiver operating characteristic (ROC) curve was used to analyze the predictive value of three indexes for postoperative recurrence and metastasis of colorectal cancer.Results:The levels of serum TAP, CYFRA21-1 and ESM1 in the colorectal cancer group were higher than those in the control group: (134.52 ± 26.18) μm 2 vs. (95.52 ± 10.03) μm 2, (6.96 ± 0.73) μg/L vs. (3.15 ± 0.42) μg/L, (36.78 ± 4.97) μg/L vs. (421 ± 0.35) μg/L, there were statistical differences ( P<0.01). There were significant differences in serum TAP, CYFRA21-1, and ESM1 levels among patients with different clinical stages, tissue differentiation, and lymph node metastasis ( P<0.01). The levels of serum TAP, CYFRA21-1 and ESM1 in the recurrence and metastasis group were higher than those in the non-recurrence and metastasis group: (155.25 ± 28.02) μm 2 vs. (121.05 ± 21.03) μm 2, (8.58 ± 0.93) μg/L vs. (5.25 ± 0.62) μg/L, (42.05 ± 5.23) μg/L vs. (34.62 ± 5.01) μg/L, there were statistical differences ( P<0.01). ROC curve analysis results showed that the combined detection of serum TAP, CYFRA21-1 and ESM1 levels predicted postoperative recurrence and metastasis of colorectal cancer patients with the largest of the area under the curve (AUC), which was 0.811, and was higher than any single index. Conclusions:The levels of TAP, CYFRA21-1 and ESM1 are increased in colorectal cancer patients, and combined detection of serum TAP, CYFRA21-1 and ESM1 levels has high predictive value for postoperative recurrence and metastasis.
